Gabapentin Capsule
Product Images NDC 85534-0055

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 85534-0055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hawaii Repack, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

An illustration showing a formula to calculate creatinine clearance (CLCr) based on age, weight, serum creatinine, and an adjustment factor for female patients.*

FDA Label Image

Structure (Gabapentin Fig 5)

Chemical structure diagram of Gabapentin showing its cyclohexane ring bonded to amino (CH2NH2) and carboxylic acid (CH2CO2H) functional groups.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph showing mean pain score over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline through 8 weeks with separate 4-week dose titration and fixed dose periods. The y-axis shows mean pain scores from 0 to 10. Gabapentin treatment shows a decreasing pain score trend, while placebo remains relatively constant.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph depicting mean pain scores over 7 weeks during a clinical study with Gabapentin. The x-axis shows time in weeks, and the y-axis shows mean pain score. Three groups are compared: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day, over a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) doses in two studies. Study 1 shows 12% responders for PBO and 29% for GBP 3600 mg. Study 2 shows 14% for PBO, 32% for GBP 1800 mg, and 34% for GBP 2400 mg, with significance levels indicated (p < 0.01, p < 0.001).*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

A scatter plot chart showing the percentage difference on the y-axis versus daily dose in mg on the x-axis for Gabapentin. The chart compares three studies (labeled a, b, and c) with data points at daily doses around 600 mg, 900 mg, 1200 mg, and 1800 mg. Study a is represented by black squares, study b by gray squares, and study c by white squares.*

FDA Label Image

Image Description (Label 100mg)

Labels for Gabapentin Capsules USP 100 mg by Hawaii Repack, Inc., distributed by Ascend Laboratories, LLC. Each label shows different package quantities: 30, 60, 90, and 120 capsules. The white hard gelatin capsules are imprinted "216" in blue ink. Labels include NDC numbers, storage instructions, federal caution, and distributor address in Honolulu, HI.*

FDA Label Image

Image Description (Label 300mg)

Four packaging labels for Gabapentin Capsules, USP 300 mg, distributed by Hawaii Repack, Inc. Each label shows different package quantities: 30, 60, 90, and 120 capsules. Labels include NDC numbers, distribution information by Ascend Laboratories, LLC, barcode, QR code, storage instructions, and a warning that federal law prohibits dispensing without prescription. The capsules are described as yellow hard gelatin with blue ink imprint '215'.*

FDA Label Image

Image Description (Label 400mg)

Label image for Gabapentin Capsules USP 400 mg distributed by Hawaii Repack, Inc. The label shows the orange hard gelatin capsules imprinted with "214" in blue ink. Available in quantities of 30, 60, 90, and 120 capsules. The label includes NDC numbers, distributor information, storage instructions, and cautionary statements about prescription status and safe storage.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.